Latest News in the pharma Industry

Research & Development

EMA validates Gilead’s MAA for investigational chronic Hep C therapy

EMA validates Gilead’s MAA for investigational chronic Hep C therapy

22 Jan 2017

Sofosbuvir/Velpatasvir/Voxilaprevir cranted an accelerated assessment by the EMA.

Read more 
FDA approves Allergan's Rhofade cream, 1% for persistent facial erythema

FDA approves Allergan's Rhofade cream, 1% for persistent facial erythema

19 Jan 2017

Once-daily treatment reduces persistent facial erythema associated with rosacea through 12 hours.

Read more 
Opdivo demonstrated efficacy and improved survival in patients with previously treated advanced gastric cancer

Opdivo demonstrated efficacy and improved survival in patients with previously treated advanced gastric cancer

19 Jan 2017

Opdivo demonstrated a 37% reduction in the risk of death compared to placebo.

Read more 
Selonterra publishes novel proprietary mechanism for APOE4 in Alzheimer’s disease

Selonterra publishes novel proprietary mechanism for APOE4 in Alzheimer’s disease

17 Jan 2017

Therapies targeted at this novel mechanism have the potential for disease-modification because they will address the genetic root cause of AD.

Read more 
New natural molecule better than morphine to be tested on humans

New natural molecule better than morphine to be tested on humans

16 Jan 2017

Opiorphin represents a new class of potent and safe painkiller.

Read more 
MicroJect Reactor technology to take centre stage in new partnership

MicroJect Reactor technology to take centre stage in new partnership

16 Jan 2017

leon nanodrugs' MJR technology offers reformulation options that address API solubility issues.

Read more 
A-Skin secures patent for groundbreaking skin engineering therapy

A-Skin secures patent for groundbreaking skin engineering therapy

16 Jan 2017

WHF therapy can be directly applied on a wound to stimulate the natural human wound healing process.

Read more 
Merck Licenses four oncology R&D programs from Vertex

Merck Licenses four oncology R&D programs from Vertex

12 Jan 2017

All programs (two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs) have first-in-class and best-in-class potential.

Read more 
FDA grants Fast-Track Designation to RHB-104 for nontuberculous mycobacteria infections

FDA grants Fast-Track Designation to RHB-104 for nontuberculous mycobacteria infections

12 Jan 2017

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation.

Read more 
Lilly and Merck expand immuno-oncology collaboration

Lilly and Merck expand immuno-oncology collaboration

11 Jan 2017

New study to evaluate combination of Lartruvo and Keytruda.

Read more 
Takeda and PvP Biologics sign development agreement around novel therapeutic for celiac disease

Takeda and PvP Biologics sign development agreement around novel therapeutic for celiac disease

9 Jan 2017

KumaMax could provide hope celiac patients who try, but are unable to completely avoid gluten exposure in their diets,

Read more 
Catalent to develop softgel capsules for JOT's leading orphan disease candidates

Catalent to develop softgel capsules for JOT's leading orphan disease candidates

9 Jan 2017

JOTROL is being developed to remedy resveratrol’s poor bioavailability and dose limiting gastrointestinal side effects.

Read more